<DOC>
	<DOC>NCT02396537</DOC>
	<brief_summary>The purpose of this study was to establish whether premedication with topical lidocaine would reduce the pain associated with IN midazolam administration in children. The study was designed to be a double-blinded, randomized, placebo-controlled trial performed in an urban, academic pediatric emergency department.</brief_summary>
	<brief_title>Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration</brief_title>
	<detailed_description>This was a double-blinded, randomized, placebo-controlled trial performed in an urban, academic pediatric emergency department with an annual census of 67,000 patients. Children 6-12 years old for whom IN midazolam was ordered were eligible for enrollment. Patients were randomly assigned an identical intranasal medication (4% Lidocaine or 0.9% saline). Patients were administered the study drug followed by IN midazolam. Patients then assigned a pain score for midazolam administration using the Wong-Baker FACES Pain Rating scale. The primary endpoint of pain score was analyzed with a two-tailed Mann-Whitney U test, with P &lt; 0.05 considered statistically significant.</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Ages 612 Previously healthy Attending physician concludes that the patient would benefit from administration of an anxiolysis medication prior to a minor procedure Moderate to severe asthma or other chronic lung disease Comorbid conditions including cerebral palsy, developmental delay, or other chronic illness deemed by the Attending physician to be unsafe to receive anxiolysis with Versed. Any child presenting with a lifethreatening condition.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Children</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Lidocaine</keyword>
	<keyword>Intranasal</keyword>
</DOC>